FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2032535154> ?p ?o ?g. }

• W2032535154 endingPage "590" @default.
• W2032535154 startingPage "585" @default.
• W2032535154 abstract "Purpose This study aimed to assess the antitumor activity of imatinib in adenoid cystic carcinoma (ACC) of the salivary gland expressing c-kit. A high level of c-kit expression has been identified in more than 90% of ACCs. Imatinib specifically inhibits autophosphorylation of the bcr-abl, platelet-derived growth factor receptor beta, and c-kit tyrosine kinases. Patients and Methods In a single-arm, two-stage, phase II clinical trial, adult patients with unresectable or metastatic ACC measurable by Response Evaluation Criteria in Solid Tumors Group criteria and expressing c-kit by immunohistochemistry were treated with imatinib 400 mg orally bid. Response was assessed every 8 weeks. Results Sixteen patients have been enrolled onto the study; 10 were female. Median age was 47 years (range, 31 to 69 years). Median Eastern Cooperative Oncology Group performance status was 1 (range, 0 to 2). Fourteen patients had lung metastases, 14 had prior radiotherapy, and six had prior chemotherapy. Toxicities occurring in at least 50% of patients included fatigue, nausea, vomiting, diarrhea, anorexia, edema, dyspnea, and/or headache, usually of mild to moderate severity. In 15 patients assessable for response, no objective responses have been observed. Nine patients had stable disease as best response. Six patients had progressive disease after two cycles. Conclusion Because of the lack of activity, the study has been stopped after the first stage and additional evaluation of imatinib in this population is not warranted. Overexpression of wild-type c-kit was not sufficient for clinical benefit from imatinib in ACC. Accrual to this study was rapid for a relatively rare cancer, encouraging additional efforts to identify more effective systemic therapy for these patients." @default.
• W2032535154 created "2016-06-24" @default.
• W2032535154 creator A5000204204 @default.
• W2032535154 creator A5021892503 @default.
• W2032535154 creator A5024173107 @default.
• W2032535154 creator A5029643115 @default.
• W2032535154 creator A5042123586 @default.
• W2032535154 creator A5047689900 @default.
• W2032535154 creator A5060092380 @default.
• W2032535154 creator A5063904421 @default.
• W2032535154 creator A5067772666 @default.
• W2032535154 creator A5070852005 @default.
• W2032535154 date "2005-01-20" @default.
• W2032535154 modified "2023-10-17" @default.
• W2032535154 title "Imatinib Mesylate in Patients With Adenoid Cystic Cancers of the Salivary Glands Expressing c-kit: A Princess Margaret Hospital Phase II Consortium Study" @default.
• W2032535154 cites W1984356170 @default.
• W2032535154 cites W1988821060 @default.
• W2032535154 cites W1997291608 @default.
• W2032535154 cites W2015015957 @default.
• W2032535154 cites W2028959752 @default.
• W2032535154 cites W2029409133 @default.
• W2032535154 cites W2031390067 @default.
• W2032535154 cites W2046632940 @default.
• W2032535154 cites W2056203481 @default.
• W2032535154 cites W2070165953 @default.
• W2032535154 cites W2082831065 @default.
• W2032535154 cites W2123607342 @default.
• W2032535154 cites W2139248078 @default.
• W2032535154 cites W2150501295 @default.
• W2032535154 cites W2248892418 @default.
• W2032535154 doi "https://doi.org/10.1200/jco.2005.06.125" @default.
• W2032535154 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15659505" @default.
• W2032535154 hasPublicationYear "2005" @default.
• W2032535154 type Work @default.
• W2032535154 sameAs 2032535154 @default.
• W2032535154 citedByCount "256" @default.
• W2032535154 countsByYear W20325351542012 @default.
• W2032535154 countsByYear W20325351542013 @default.
• W2032535154 countsByYear W20325351542014 @default.
• W2032535154 countsByYear W20325351542015 @default.
• W2032535154 countsByYear W20325351542016 @default.
• W2032535154 countsByYear W20325351542017 @default.
• W2032535154 countsByYear W20325351542018 @default.
• W2032535154 countsByYear W20325351542019 @default.
• W2032535154 countsByYear W20325351542020 @default.
• W2032535154 countsByYear W20325351542021 @default.
• W2032535154 countsByYear W20325351542022 @default.
• W2032535154 countsByYear W20325351542023 @default.
• W2032535154 crossrefType "journal-article" @default.
• W2032535154 hasAuthorship W2032535154A5000204204 @default.
• W2032535154 hasAuthorship W2032535154A5021892503 @default.
• W2032535154 hasAuthorship W2032535154A5024173107 @default.
• W2032535154 hasAuthorship W2032535154A5029643115 @default.
• W2032535154 hasAuthorship W2032535154A5042123586 @default.
• W2032535154 hasAuthorship W2032535154A5047689900 @default.
• W2032535154 hasAuthorship W2032535154A5060092380 @default.
• W2032535154 hasAuthorship W2032535154A5063904421 @default.
• W2032535154 hasAuthorship W2032535154A5067772666 @default.
• W2032535154 hasAuthorship W2032535154A5070852005 @default.
• W2032535154 hasBestOaLocation W20325351541 @default.
• W2032535154 hasConcept C121608353 @default.
• W2032535154 hasConcept C126322002 @default.
• W2032535154 hasConcept C143998085 @default.
• W2032535154 hasConcept C2776694085 @default.
• W2032535154 hasConcept C2777546739 @default.
• W2032535154 hasConcept C2777583451 @default.
• W2032535154 hasConcept C2778039489 @default.
• W2032535154 hasConcept C2778729363 @default.
• W2032535154 hasConcept C2778822529 @default.
• W2032535154 hasConcept C2779231225 @default.
• W2032535154 hasConcept C2780580376 @default.
• W2032535154 hasConcept C2908647359 @default.
• W2032535154 hasConcept C3019892230 @default.
• W2032535154 hasConcept C31760486 @default.
• W2032535154 hasConcept C71924100 @default.
• W2032535154 hasConcept C90924648 @default.
• W2032535154 hasConcept C99454951 @default.
• W2032535154 hasConceptScore W2032535154C121608353 @default.
• W2032535154 hasConceptScore W2032535154C126322002 @default.
• W2032535154 hasConceptScore W2032535154C143998085 @default.
• W2032535154 hasConceptScore W2032535154C2776694085 @default.
• W2032535154 hasConceptScore W2032535154C2777546739 @default.
• W2032535154 hasConceptScore W2032535154C2777583451 @default.
• W2032535154 hasConceptScore W2032535154C2778039489 @default.
• W2032535154 hasConceptScore W2032535154C2778729363 @default.
• W2032535154 hasConceptScore W2032535154C2778822529 @default.
• W2032535154 hasConceptScore W2032535154C2779231225 @default.
• W2032535154 hasConceptScore W2032535154C2780580376 @default.
• W2032535154 hasConceptScore W2032535154C2908647359 @default.
• W2032535154 hasConceptScore W2032535154C3019892230 @default.
• W2032535154 hasConceptScore W2032535154C31760486 @default.
• W2032535154 hasConceptScore W2032535154C71924100 @default.
• W2032535154 hasConceptScore W2032535154C90924648 @default.
• W2032535154 hasConceptScore W2032535154C99454951 @default.
• W2032535154 hasIssue "3" @default.
• W2032535154 hasLocation W20325351541 @default.
• W2032535154 hasLocation W20325351542 @default.
• W2032535154 hasOpenAccess W2032535154 @default.

• next